GLP-1 receptor agonists combined with SGLT2 inhibitors reduce all-cause mortality compared to SGLT2 inhibitor monotherapy
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.